491 related articles for article (PubMed ID: 28436380)
1. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
Lee SH; Cheon GJ; Kim HS; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS; Jun BG; Don Kim Y; Jun DW; Sohn JH; Kim TY; Lee BS
Antivir Ther; 2018; 23(3):219-227. PubMed ID: 28436380
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
5. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Park JG; Park SY
Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
[TBL] [Abstract][Full Text] [Related]
6. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
[No Abstract] [Full Text] [Related]
7. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
[TBL] [Abstract][Full Text] [Related]
9. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Lim YS; Yoo BC; Byun KS; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 Jun; 65(6):1042-51. PubMed ID: 25800784
[TBL] [Abstract][Full Text] [Related]
11. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.
Liu Y; Wu C; Chen R; Li X; Xu Z; Li Q; Li L; Wang FS; Yang D; Lu M; Xu D
Antivir Ther; 2019; 24(4):237-246. PubMed ID: 30882363
[TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
15. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Lee YB; Lee JH; Lee DH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
Antimicrob Agents Chemother; 2014 Nov; 58(11):6710-6. PubMed ID: 25155601
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir.
Jeon HJ; Jung SW; Park NH; Yang Y; Noh JH; Ahn JS; Kim HR; Lee JH; Shin JW
Clin Mol Hepatol; 2017 Sep; 23(3):230-238. PubMed ID: 28669175
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.
Lim YS; Byun KS; Yoo BC; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 May; 65(5):852-60. PubMed ID: 25596179
[TBL] [Abstract][Full Text] [Related]
20. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Yuan G; Hu C; Zhou Y; Liu J; Huang H; Li Y; Yang D; Zhou F; Zhang YY; Zhou Y
Br J Clin Pharmacol; 2017 Oct; 83(10):2259-2265. PubMed ID: 28511283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
